tetano
Editor, Senior Moderator
Clin Vaccine Immunol. 2011 Oct 26. [Epub ahead of print]
Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza.
Hossain MJ, Bourgeois M, Quan FS, Lipatov AS, Song JM, Chen LM, Compans RW, York I, Kang SM, Donis RO.
Source
Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA.
Abstract
Immunization of the world population before an influenza pandemic such as the 2009 H1N1 spreads globally is not possible with current vaccine production platforms. New influenza vaccine technologies, such as virus-like-particles (VLP), offer a promising alternative. Here, we tested the immunogenicity and protective efficacy of a VLP vaccine containing HA and M1 from the 2009 pandemic H1N1 influenza virus (H1N1pdm) in ferrets and compared IM and IN routes of immunization. Vaccination of ferrets with VLPs containing the M1 and HA proteins from A/California/04/2009 (H1N1pdm) induced high antibody titers and conferred significant protection against virus challenge. VLP-vaccinated animals lost less weight, shed less virus in nasal washes, and had markedly lower virus titers in all organs tested than na?ve controls. A single dose of VLPs, either IM or IN, induced higher levels of antibody than did two doses of commercial split vaccine. Ferrets vaccinated with split vaccine were incompletely protected against challenge; these animals had lower virus titers in olfactory bulbs, tonsils, and intestines, but lost weight and shed virus in nasal washes to a similar extent as na?ve controls. Challenge with heterologous A/Brisbane/59/07 (H1N1) virus revealed that the VLPs conferred minimal cross-protection to heterologous infection as revealed by the lack of reduction in nasal wash and lung virus titers and slightly higher weight loss relative to controls. In summary, these experiments demonstrate the strong immunogenicity and protective efficacy of VLPs compared to the split vaccine, and show that IN vaccination with VLPs has the potential for highly efficacious vaccination against influenza.
PMID:
22030367
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22030367
Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza.
Hossain MJ, Bourgeois M, Quan FS, Lipatov AS, Song JM, Chen LM, Compans RW, York I, Kang SM, Donis RO.
Source
Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA.
Abstract
Immunization of the world population before an influenza pandemic such as the 2009 H1N1 spreads globally is not possible with current vaccine production platforms. New influenza vaccine technologies, such as virus-like-particles (VLP), offer a promising alternative. Here, we tested the immunogenicity and protective efficacy of a VLP vaccine containing HA and M1 from the 2009 pandemic H1N1 influenza virus (H1N1pdm) in ferrets and compared IM and IN routes of immunization. Vaccination of ferrets with VLPs containing the M1 and HA proteins from A/California/04/2009 (H1N1pdm) induced high antibody titers and conferred significant protection against virus challenge. VLP-vaccinated animals lost less weight, shed less virus in nasal washes, and had markedly lower virus titers in all organs tested than na?ve controls. A single dose of VLPs, either IM or IN, induced higher levels of antibody than did two doses of commercial split vaccine. Ferrets vaccinated with split vaccine were incompletely protected against challenge; these animals had lower virus titers in olfactory bulbs, tonsils, and intestines, but lost weight and shed virus in nasal washes to a similar extent as na?ve controls. Challenge with heterologous A/Brisbane/59/07 (H1N1) virus revealed that the VLPs conferred minimal cross-protection to heterologous infection as revealed by the lack of reduction in nasal wash and lung virus titers and slightly higher weight loss relative to controls. In summary, these experiments demonstrate the strong immunogenicity and protective efficacy of VLPs compared to the split vaccine, and show that IN vaccination with VLPs has the potential for highly efficacious vaccination against influenza.
PMID:
22030367
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22030367